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. Differential gene expression was analyzed using 3 different statistical methods as described 2 .
Mass cytometry. Immediately prior to running on the mass cytometer, cells were resuspended at approximately 0.8x10 6 cells/mL in EQ TM Four Element Calibration Beads (Fluidigm Sciences). Calibration beads were used to correct signal fluctuation as previously described 3 . All data were analyzed with Cytobank software (www.Cytobank.com). ViSNE analyses were performed as described 4 . All surface markers were used to create the viSNE map with the exception of CD107a. Protein expression on the viSNE maps is shown with an arcsinh transformation. Stimulation and detection of phospho-protein signaling was performed as previously described 5 .
After staining, cells were washed twice in PBS and run on a 5-laser LSRII (Becton Dickinson). Data were analyzed with Cytobank software. Median fluorescent intensities were arcsinh-transformed and fold change calculated by the table's minimum value 6 .
Phospho-flow. Briefly, samples were thawed and 2x10 6 were removed for immunophenotyping by mass cytometry and remainder of the sample was used for phospho-flow cytometry. Cells rested for 30 minutes at 37 °C prior to stimulation. Cells were aliquoted into FACs tubes and allowed to rest for 5 additional minutes. Signaling was activated by stimulation with 20 ng/mL (final concentration) of IL-2, IL-4, IL-7, IL-9, IL-21, or IFNγ for 15 minutes at 37 °C. Signaling was stopped by fixation with the addition of a final concentration of 1.6% paraformaldehyde (Electron Microscopy Sciences) and incubation for 15 minutes at room temperature. Cells were washed twice with PBS/1% BSA and permeabilized with >90% ice-cold methanol. Cells were rehydrated in PBS and washed once in PBS/1%BSA. Cells were stained with 50 μL PBS/1% BSA containing antibody cocktail for 30 minutes at room temperature (protected from light). See supplemental Table below for list of antibodies used in this study.
Phosphatase enzyme assay. One to five million Jurkat or primary T-cell PLL cells were lysed in hypotonic buffer (50 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, with Roche protease inhibitors minitab) by trituration and clarified by centrifugation at 20,000xg. Potato Acid phosphatase was used as positive control (Sigma). Enzyme assays were done using 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) substrate (Molecular Probes) in 50 mM HEPES, pH 7.4 and 1 µg cytosol at 25 °C. Standard curves for quantification of DiFMUP were generated using 6,8-difluoro-7-hydroxy-4-methylcoumarin (Molecular Probes). All assays including enzyme kinetics were performed on a BioTek Synergy H1 instrument. CD45 was immunodepleted from leukemic cell cytosol with 5 µg anti-CD45 (EMDMillipore) and 20 µl of Protein A/G-agarose (Santa Cruz) for 2h at 4 °C and nonspecific isotype control IgG was used as control. Figure S1 . Tile plot of all mutations found in 91 cases of T-cell neoplasms. Figure 1 of the paper shows a similar tile plot but only for those mutations that were recurrent. Figure S2 . Mutation frequency in T-cell neoplasms compared to Diffuse Large B-cell lymphoma (DLBCL). Similar to whole genome and exome sequencing studies, we observed a higher frequency of transitions over transversions but these T-cell neoplasms also showed a high frequency of G>T transversions (23/158, 14%) . To compare these mutation frequencies, we analyzed 193 diffuse large B-cell lymphomas (DLBCL) by the same workflow and platforms. Among these DLBCL cases, G>T transversions comprised 3% (28/880) of total mutations, significantly less common than within the T-cell neoplasms (14% v. 3%, P<.0001, see supplemental Figure S2 and Table S1 ). Bar graphs show frequency of transition and transversion mutations in 91 cases of Tcell neoplasms described in this study (panel A) and 185 cases of DLBCL that were analyzed on the same platform (panel B). The frequencies shown are based on 158 total mutations in T-cell neoplasms and 880 total mutations in DLBCL. The G>T transversion was detected at 13.9% in T-cell neoplasms and was significantly increased in comparison to DLBCL cases based on Fisher exact test, P<0.0001. Interestingly, TET2 (12% v. 5.2%, P=0.05) and DNMT3A (7.7% v. 1.0%, P=0.0055) mutations were more common in T-cell neoplasms than DLBCL cases. Figure S3 . JAK1 and JAK3 mutant mRNAs expressed in pre-and post-ruxolitinib samples. RNA-seq was performed on duplicate poly(A)-selected RNA isolated form T-PLL cells before and after ruxolitinib treatment. Sequence files were visualized in the Integrated Genome Viewer (IGV), which also counted the allele frequencies shown as bars of different color above the horizontal gray bars signifying reads. Codon 658 in JAK1 showed a GTC>TTC mutation. Codon 511 in JAK3 was mutated ATG>ATT. Mutant JAK1 mRNA was 44% of transcripts versus 56% wild type in the pre-ruxolitinib sample and 9% mutant and 91% WT in post-ruxolitinib sample. Mutant JAK3 mRNA was 10% mutant and 90% WT in the pre-ruxolitinib sample and 50% mutant and 50% WT in the post-ruxolitinib sample. . T-PLL case relapsed after CHOP chemotherapy shows CD45 downregulation and clonal JAK3 M511I mutation. We found a case where CD45 expression was downregulated after relapse from CHOP chemotherapy. The pre-treatment sample was not banked but the relapsed sample showed a downregulation of CD45 protein in panel A, CD45 versus SSC (side scatter). Panel B shows CD5+CD19-CD4+CD8+ T-PLL. We performed standard Sanger sequencing on the relapse sample and discovered a clonal JAK3 M511I mutation, the same mutation found in the index case presented in this paper. Table S4 . Frequencies of various mutations and features among T-cell neoplasms. Our cohort of 91 T-cell neoplasms were divided into mature (n=66) and immature (n=25) based on standard WHO pathologic classification. Number of cases for each of these is shown followed by statistical comparison of frequencies in immature and mature T-cell neoplasms by Fisher exact test.
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Tumor type gene mutation AITL3
RHOA_c
FAS_c.580G>T
T-PLL5
JAK3_c.1533G>T Table S5 . Cases with G>T transversion mutations.
subtype
KNOWN SOMATIC SHORT-VARIANTS (PERCENT-READS,COVERAGE) LIKELY SOMATIC SHORT-VARIANTS (PERCENT-READS, COVERAGE)
T-PLL1 Table S6 . Cases with JAK1 or JAK3 mutations and other select mutations. Table S7 . Mutations identified in the T-PLL index case. MAF , mean allele frequencies in %, pre-ruxolitinib and post-ruxolitinib, followed by number of reads analyzed. PerCP-Cy5.5 BD Phosflow 561195 Table S8 . List of select antibodies used in flow cytometry in this study.
Conjugate
Antigen Antibody clone Vendor Cat no. AKT3  ATR  AXIN1  B2M  BCL6  BCORL1  CD274  CDH1  CDK12  CHEK2  CIC  CPS1  DDX3X  ERBB2  EZH2  FAF1  FANCA  FANCM  FGF10  FGFR1  FGFR4  FLT3  GATA3  GRIN2A  HIST1H2AC  HIST1H2AM  HIST1H2BJ  HNF1A  ICK  IKBKE  IKZF1  IL7R  KIT  LEF1  LRP1B  MAP3K13  MAP3K6  MDM2  MDM4  MED12  MLH1  MLL  MUTYH  MYCN  NCOR2  PCLO  PDCD11  PDGFRA  RAD50  RAD52  RARA  RET  RICTOR  SMAD4  SOX10  SPEN  SRSF2  SUZ12  TBL1XR1  TP63  TRRAP  TSC2  U2AF1  ZRSR2  APC  ASXL1  BCOR  BRCA2  CARD11  CCND3  CDKN1B  CIITA  CREBBP  ETV6  HIST1H1D  IDH2  JAK2  KRAS  NCOR1  NUP214  PASK  PHF6  PIK3CA  PTEN  RB1  SETD2  SMARCA4  SMARCB1  TNFAIP3  VHL  ALK  ATM  CD36  FAS  NF1  PIK3R1  RUNX1  STAG2  STAT5A  TRAF3  WT1  ABL1  FBXW7  STAT5B  ARID1A  MLL2  RHOA  JAK1  DNMT3A  NRAS  STAT3  TP53  JAK3  NOTCH1  TET2  CDKN2A/B   AITL1  AITL2  AITL3  AITL4  AITL5  AITL6  AITL7  AITL8  ALCL1  ALCL2  ALCL3  ALCL4  ALCL5  ALCL6  ALCL7  CTCL1  CTCL2  CTCL3  CTCL4  CTCL5  CTCL6  CTCL7  CTCL8  CTCL9  CTCL10  CTCL11  CTCL12  CTCL13  CTCL14  NK/T1  NK/T2  NK/T3  PTCL1  PTCL2  PTCL3  PTCL4  PTCL5  PTCL6  PTCL7  PTCL8  PTCL9  PTCL10  PTCL11  PTCL12  PTCL13  PTCL14  PTCL15  PTCL16  T 
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